SCHEMBL30285722

SCHEMBL30285722

O=C(Cc1cccc(F)c1Cl)Nc1cnnc(Nc2cccc(F)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 2/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.43
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ TSHR P16473 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ KCNJ5 P48544 2/20 0.39
▸ KCNJ3 P48549 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ ERBB2 P04626 1/20 0.39
▸ P2RX4 Q99571 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ POLB P06746 1/20 0.37
▸ ELOVL1 Q9BW60 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24173311 1.00 ANO1 (0.46) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL24173312 0.93 ANO1 (0.47) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL30285757 0.93 ANO1 (0.47) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL30285888 0.92 ANO1 (0.48) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL26186445 0.92 ANO1 (0.48) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL30285633 0.91 ALDH1A1 (0.49) ANO1SMN1; SMN2ALDH1A1KMT2ATSHR
SCHEMBL26186449 0.91 ALDH1A1 (0.49) ANO1SMN1; SMN2ALDH1A1KMT2ATSHR
SCHEMBL30285782 0.90 ANO1 (0.46) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL26186458 0.90 ANO1 (0.46) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL30285655 0.89 KCNJ5 (0.53) ANO1SMN1; SMN2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN claimed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 — — US disclosed
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY P2RX2, P2RX5, P2RX3 ANO1 964/4885SMN1; SMN2 1553/4885ALDH1A1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback